Evidence map›Paper›PMID 41701357›Full record

ArticleJournal of molecular medicine (Berlin, Germany)2026

Anti-myeloma activity of the CXCR4 antagonist WZ811.

Danka Cholujova, Nikoleta Csicsatkova, Zuzana Valuskova, Katarina Suroviakova, Maria Elisabeth Marinkovicova, Anna Strizova, Jan Sedlak, Jana Jakubikova

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of molecular medicine (Berlin, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Danka CholujovaCancer Research Institute, Department of Tumor Immunology, Biomedical Research Center, V. V. I, Slovak Academy of Sciences, Dubravska Cesta 9, 84505, Bratislava, Slovakia.
Nikoleta CsicsatkovaCancer Research Institute, Department of Tumor Immunology, Biomedical Research Center, V. V. I, Slovak Academy of Sciences, Dubravska Cesta 9, 84505, Bratislava, Slovakia.
Zuzana ValuskovaCancer Research Institute, Department of Tumor Immunology, Biomedical Research Center, V. V. I, Slovak Academy of Sciences, Dubravska Cesta 9, 84505, Bratislava, Slovakia.
Katarina SuroviakovaCancer Research Institute, Department of Tumor Immunology, Biomedical Research Center, V. V. I, Slovak Academy of Sciences, Dubravska Cesta 9, 84505, Bratislava, Slovakia.
Maria Elisabeth MarinkovicovaCancer Research Institute, Department of Tumor Immunology, Biomedical Research Center, V. V. I, Slovak Academy of Sciences, Dubravska Cesta 9, 84505, Bratislava, Slovakia.
Anna StrizovaCancer Research Institute, Department of Tumor Immunology, Biomedical Research Center, V. V. I, Slovak Academy of Sciences, Dubravska Cesta 9, 84505, Bratislava, Slovakia.
Jan SedlakCancer Research Institute, Department of Tumor Immunology, Biomedical Research Center, V. V. I, Slovak Academy of Sciences, Dubravska Cesta 9, 84505, Bratislava, Slovakia.
Jana JakubikovaCancer Research Institute, Department of Tumor Immunology, Biomedical Research Center, V. V. I, Slovak Academy of Sciences, Dubravska Cesta 9, 84505, Bratislava, Slovakia. jana.jakubikova@savba.sk.ORCID http://orcid.org/0000-0003-2593-569X

Funding

Agentúra na Podporu Výskumu a Vývoja APVV-19-0212Agentúra na Podporu Výskumu a Vývoja APVV-20-0183Agentúra na Podporu Výskumu a Vývoja APVV-21-0215Agentúra na Podporu Výskumu a Vývoja APVV-23-0482Agentúra na Podporu Výskumu a Vývoja APVV-24-0471NextGenerationEU project No. 09I03-03-V02-00031NextGenerationEU project No.09I03-03-V04-00451Research & Innovation Operational Programme funded by the ERDF ITMS project code 313021T081Vedecká Grantová Agentúra MŠVVaŠ SR a SAV VEGA 2/0087/23Vedecká Grantová Agentúra MŠVVaŠ SR a SAV VEGA 2/0088/23
6 · The paper itself

Abstract

The CXCR4-CXCL12 axis is crucial for the interaction between malignant plasma cells (PC) and their microenvironment in multiple myeloma (MM). Here, we show that CXCR4 expression is upregulated in MM cell lines and PCs during both premalignant and active stages of MM, compared to normal PCs from healthy donors. The CXCR4 antagonist WZ811 reduced the viability of MM PCs and cell lines, while tumor microenvironment cells from both MM patients and healthy donors exhibited significant resistance. In vivo, WZ811 significantly reduced tumor burden and improved survival. WZ811-mediated MM cell death involved disruption of mitochondrial transmembrane potential, externalization of transmembrane phosphatidylserine, activation of caspases, increased levels of autophagic proteins, and an increase in G

Indexed as

Antineoplastic AgentsMultiple MyelomaReceptors, CXCR4AnimalsApoptosisCell Line, TumorCell SurvivalChemokine CXCL12HumansMicePlasma CellsTumor MicroenvironmentXenograft Model Antitumor AssaysAntineoplastic AgentsChemokine CXCL12CXCR4 protein, humanReceptors, CXCR4CXCR4Multiple myelomaMyeloma stem cell-like side populationTumor microenvironment

Identifiers

PMID41701357
PMCPMC12913330

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.